Citation Tools
Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study